Renovacor ships its cardiac gene therapy to Rocket in $53M all-stock deal
Renovacor wanted to be in the clinic already. The biotech expected an $11 million Series A in summer 2019 would bankroll an IND filing for its cardiac gene therapy, but as it goes with drug R&D, the path took some twists.
Fifty-four weeks after shipping up to New York City for a blank check merger, Renovacor is turning off the lights on $RCOR and going the way of $RCKT, or Rocket Pharmaceuticals, in an all-stock deal that adds to the latter’s gene therapy ambitions, which includes two likely BLA filings next year.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.